Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdOx1-HBV
- Development stage
- Phase 2
- Lead developer
- Barinthus Biotherapeutics
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAdOx1-HBV is a therapeutic vaccine candidate designed to induce a functional cure in patients chronically infected with hepatitis B virus (HBV). It uses a non-replicative chimpanzee adenoviral vector (ChAdOx1) to deliver HBV antigens, specifically encoding genotype C HBV core, polymerase, and surface antigens. The vaccine aims to stimulate robust HBV-specific T cell responses targeting all major viral antigens. In phase I clinical studies, ChAdOx1-HBV was found to be safe and well tolerated in both healthy volunteers and patients with chronic hepatitis B infection. The immunogenicity was high in healthy individuals but attenuated in those with chronic infection. Further development includes combination strategies with other immunotherapies to enhance efficacy for chronic hepatitis B[1][2][5].
- Other names
- VTP-300VTP300VTP 300
02
Targets
HBcAg-pMHC (Hepatitis B virus core antigen-derived peptides presented on Major Histocompatibility Complex molecules)Hepatitis B virus polymerase-derived peptide-MHC complexHBsAg S20-28/HLA-A*02:01 (HBsAg S20-28 peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on ChAdOx1-HBV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdOx1-HBV.